AFP and hepatocellular carcinoma: To resolve these uncertainties and controversies, we aim to evaluate the diagnostic accuracy of PIVKA-II compared to AFP to differentiate HCC from non-malignant high-risk (NMHR) group patients at our centre and to determine their cut-off values.